Article ; Online: Maternal serotonin: implications for the use of selective serotonin reuptake inhibitors during gestation†.
2024 Volume 109, Issue 1, Page(s) 17–28
Abstract: Maternal use of antidepressants has increased throughout the last decades; selective serotonin reuptake inhibitors (SSRI) are the most prescribed antidepressants. Despite the widespread use of SSRI by women during reproductive age and pregnant women, an ... ...
Abstract | Maternal use of antidepressants has increased throughout the last decades; selective serotonin reuptake inhibitors (SSRI) are the most prescribed antidepressants. Despite the widespread use of SSRI by women during reproductive age and pregnant women, an increasing amount of research warns of possible detrimental effects of maternal use of SSRI during pregnancy including low birthweight/small for gestational age and preterm birth. In this review, we revisited the impact of maternal use of SSRI during pregnancy, its impact on serotonin homeostasis in the maternal and fetal circulation and the placenta, and its impact on pregnancy outcomes-particularly intrauterine growth restriction and preterm birth. Maternal use of SSRI increases maternal and fetal serotonin. The increase in maternal circulating serotonin and serotonin signaling likely promotes vasoconstriction of the uterine and placental vascular beds decreasing blood perfusion to the uterus and consequently to the placenta and fetus with potential impact on placental function and fetal development. Several adverse pregnancy outcomes are similar between women, sheep, and rodents (decreased placental size, decreased birthweight, shorter gestation length/preterm birth, neonatal morbidity, and mortality) highlighting the importance of animal studies to assess the impacts of SSRI. Herein, we address the complex interactions between maternal SSRI use during gestation, circulating serotonin, and the regulation of blood perfusion to the uterus and fetoplacental unit, fetal growth, and pregnancy complications. |
---|---|
MeSH term(s) | Infant, Newborn ; Female ; Pregnancy ; Humans ; Animals ; Sheep ; Selective Serotonin Reuptake Inhibitors/adverse effects ; Serotonin/pharmacology ; Premature Birth/chemically induced ; Birth Weight ; Placenta ; Antidepressive Agents/adverse effects ; Pregnancy Outcome |
Chemical Substances | Selective Serotonin Reuptake Inhibitors ; Serotonin (333DO1RDJY) ; Antidepressive Agents |
Language | English |
Publishing date | 2024-04-04 |
Publishing country | United States |
Document type | Review ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't |
ZDB-ID | 1118-6 |
ISSN | 1529-7268 ; 0006-3363 |
ISSN (online) | 1529-7268 |
ISSN | 0006-3363 |
DOI | 10.1093/biolre/ioad046 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 551: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.